SynthesisDermatologie (Heidelberg, Germany)2026
[The role of serological (rapid) tests for the early detection of HPV-related cancers].
Synthesis in Dermatologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncogenic human papillomaviruses (HPV), such as HPV16, can cause anogenital and oropharyngeal cancer (OPC). Unlike anogenital cancers, there are no known premalignant precursor lesions for HPV-induced OPC (HPV-OPC). While cytology-based and HPV-DNA/mRNA-based screening programs are recommended for anogenital cancers in the general population (cervical cancer) or for high-risk groups (anal cancer), this is not the case for HPV-OPC. This article summarizes the role of HPV serology for the early detection of HPV-OPC. The detection of antibodies against the HPV16 oncoprotein E6 has been investigated in many studies. In a systematic review with meta-analysis, a pooled sensitivity of 83.1% and a specificity of 94.6% were calculated for the detection of HPV-OPC with HPV16-E6 serology. The HPV16-E6 antibodies can be detected in serum many years before an OPC diagnosis. At present, however, there is still no validated management approach for individuals who test positive for HPV16-E6 antibodies but are clinically tumor-free. In contrast to HPV-E6 antibodies, antibodies against the HPV capsid protein L1 are detectable following HPV vaccination and also following natural HPV infection in individuals without cancer. In Germany and other countries, a CE in vitro diagnostics (IVD)-labelled rapid test for the detection of HPV16-L1 antibodies (Prevo-Check®) is marketed for the early detection of HPV16-induced cancer. In a recent study, the HPV16-L1 rapid test yielded a positive result in only one quarter of patients with HPV16-OPC. Nearly all HPV vaccinated individuals, as well as more than one third of young people who had experienced a natural HPV16 infection, also tested positive with the HPV16-L1 rapid test. Due to its low sensitivity (12.5-25%) and a high rate of false positive test results, the HPV16-L1 rapid test is not suitable for screening for HPV-OPC.
Indexed as
Identifiers
42696122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.